<DOC>
	<DOCNO>NCT00976417</DOCNO>
	<brief_summary>It know significant proportion patient heart failure sleep disorder breathing ( SDB ) . Some patient Central Sleep Apnoea one form SDB . The SERVE-HF study aim look effect breathe support machine , ventilator call Adaptive Servo-ventilation ( ASV ) mortality heart failure patient central sleep apnoea . In related sub-study investigator want look ASV machine effect . The investigator carry test laboratory measure various aspect way breathe controlled measure effect ASV patient . In addition measurement look activity level make use actiwatch device wear patient 14 consecutive day night . Healthy control recruited part protocol ( ie measurement baseline 3 month ) allow comparison data patient control .</brief_summary>
	<brief_title>Mechanisms Action Adaptive Servoventilation</brief_title>
	<detailed_description>As part wider study interested patient fail heart breathe sleep . It known patient heart failure central sleep apnoea ( form breathing difficulty sleep ) poor prognosis . It likely condition place extra strain heart . We want investigate whether treat breathe problem benefit group patient . The propose study investigate significant proportion patient heart failure central sleep apnoea respond treatment . We measure factor contribute breathe : ( ) How brain change breathe rate depth response change carbon dioxide level ( Chemosensitivity ) ; ( ii ) How blood vessel brain change response change carbon dioxide level ( Cerebral Vascular Reactivity ) ; ( iii ) An overall measure breathe control call `` Loop Gain '' ( protocol undertake subgroup patient give specific consent ) . These measurement carry laboratory patient take part SERVE-HF ; multicentre randomise control study adaptive servoventilation ( ASV ) . ASV form non-invasive ventilation ( deliver mask worn face ) show previous small study adequately suppress sleep disorder breathing . The propose study allow u take measurement patient assigned treatment control group ; compare measurement make group start treatment three month . In addition measurement look activity level make use actiwatch device wear patient 14 consecutive day night . Previously demonstrate heart failure patient sleep disordered breathe low level daytime activity compare heart failure patient without sleep disorder breathing . We investigate effect ASV activity measurement patient sleep disordered breathing . Healthy control recruited part protocol ( ie measurement baseline 3 month ) allow comparison data patient control .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<criteria>Over 18 year age Severe Chronic Heart Failure ( CHF ) NYHA class IIIIV NYHA class II least one hospitalisation HF within last 12 month Left ventricular ejection fraction ( LVEF ) &lt; 40 % mean echocardiography , radionucleotide angiography , leave ventriculography cardiac MRI document less 12 week randomisation Diagnosis sleep disorder breathe SDB ( apnoeahypopnoeaindex ( AHI &gt; 15/h ) ≥ 50 % central event central AHI ≥ 10/h ) Clinically stable change medication hospitalisation precede month Optimised medical treatment accord applicable guideline Able provide inform consent Significant chronic obstructive pulmonary disease ( COPD ) Forced Expiratory Volume within one second ( FEV1 ) &lt; 50 % Oxygen saturation rest day ≤ 90 % inclusion Current use Positive Airway Pressure ( PAP ) therapy Life expectancy &lt; 1 year disease unrelated chronic heart failure Cardiac surgery , Percutaneous coronary intervention ( PCI ) , Myocardial Infarction ( MI ) unstable angina within 6 month prior randomisation Implantation ICD ( implanted cardiodefibrillator ) CRT ( cardiac resynchronisation therapy ) schedule within 6 month prior randomisation Transient ischemic attack ( TIA ) Stroke within 3 month prior randomisation Primary hemodynamically significant uncorrected valvular heart disease , obstructive regurgitant , valvular disease expect lead surgery trial Acute myocarditis/pericarditis within 6 month prior randomisation Untreated therapy refractory Restless legs Syndrome ( RLS ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>